Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Medtronic
McKesson
AstraZeneca
McKinsey

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Selumetinib

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Selumetinib?

Selumetinib is an investigational drug.

There have been 89 clinical trials for Selumetinib. The most recent clinical trial was a Phase 2 trial, which was initiated on December 2nd 2019.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Neurofibromatoses. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Cancer Research UK.

There are ninety-one US patents protecting this investigational drug and eight hundred and two international patents.

Recent Clinical Trials for Selumetinib
TitleSponsorPhase
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaNational Cancer Institute (NCI)Phase 3
Selumetinib Versus Carboplatin/Vincristine in Treating Patients With Newly Diagnosed or Previously Untreated NF1-Associated Low-Grade GliomaNational Cancer Institute (NCI)Phase 3
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)Merck Sharp & Dohme Corp.Phase 1

See all Selumetinib clinical trials

Clinical Trial Summary for Selumetinib

Top disease conditions for Selumetinib
Top clinical trial sponsors for Selumetinib

See all Selumetinib clinical trials

US Patents for Selumetinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Selumetinib   Start Trial Organic compositions to treat beta-catenin-related diseases Arrowhead Pharmaceuticals, Inc. (Pasadena, CA)   Start Trial
Selumetinib   Start Trial Compositions and methods for epithelial stem cell expansion and culture Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
Selumetinib   Start Trial Compositions and methods for epithelial stem cell expansion and culture Massachusetts Institute of Technology (Cambridge, MA) The Brigham and Women's Hospital, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Baxter
McKinsey
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.